Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 5
2009 1
2012 1
2013 1
2014 1
2015 1
2016 1
2017 2
2018 2
2019 2
2020 3
2021 4
2022 5
2023 9
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

37 results

Results by year

Filters applied: . Clear all
Page 1
Dabigatran versus warfarin in patients with atrial fibrillation.
Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L; RE-LY Steering Committee and Investigators. Connolly SJ, et al. N Engl J Med. 2009 Sep 17;361(12):1139-51. doi: 10.1056/NEJMoa0905561. Epub 2009 Aug 30. N Engl J Med. 2009. PMID: 19717844 Free article. Clinical Trial.
Outcomes after Angiography with Sodium Bicarbonate and Acetylcysteine.
Weisbord SD, Gallagher M, Jneid H, Garcia S, Cass A, Thwin SS, Conner TA, Chertow GM, Bhatt DL, Shunk K, Parikh CR, McFalls EO, Brophy M, Ferguson R, Wu H, Androsenko M, Myles J, Kaufman J, Palevsky PM; PRESERVE Trial Group. Weisbord SD, et al. N Engl J Med. 2018 Feb 15;378(7):603-614. doi: 10.1056/NEJMoa1710933. Epub 2017 Nov 12. N Engl J Med. 2018. PMID: 29130810 Free article. Clinical Trial.
Hierarchically structured bioinspired nanocomposites.
Nepal D, Kang S, Adstedt KM, Kanhaiya K, Bockstaller MR, Brinson LC, Buehler MJ, Coveney PV, Dayal K, El-Awady JA, Henderson LC, Kaplan DL, Keten S, Kotov NA, Schatz GC, Vignolini S, Vollrath F, Wang Y, Yakobson BI, Tsukruk VV, Heinz H. Nepal D, et al. Nat Mater. 2023 Jan;22(1):18-35. doi: 10.1038/s41563-022-01384-1. Epub 2022 Nov 28. Nat Mater. 2023. PMID: 36446962 Review.
Telmisartan, ramipril, or both in patients at high risk for vascular events.
ONTARGET Investigators; Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C. ONTARGET Investigators, et al. N Engl J Med. 2008 Apr 10;358(15):1547-59. doi: 10.1056/NEJMoa0801317. Epub 2008 Mar 31. N Engl J Med. 2008. PMID: 18378520 Free article. Clinical Trial.
Design of amyloidogenic peptide traps.
Sahtoe DD, Andrzejewska EA, Han HL, Rennella E, Schneider MM, Meisl G, Ahlrichs M, Decarreau J, Nguyen H, Kang A, Levine P, Lamb M, Li X, Bera AK, Kay LE, Knowles TPJ, Baker D. Sahtoe DD, et al. Nat Chem Biol. 2024 Mar 19. doi: 10.1038/s41589-024-01578-5. Online ahead of print. Nat Chem Biol. 2024. PMID: 38503834
Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial.
Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators; Yusuf S, Teo K, Anderson C, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P. Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators, et al. Lancet. 2008 Sep 27;372(9644):1174-83. doi: 10.1016/S0140-6736(08)61242-8. Epub 2008 Aug 29. Lancet. 2008. PMID: 18757085 Clinical Trial.
The British Orthopaedic Oncology Management (BOOM) audit.
Archer JE, Chauhan GS, Dewan V, Osman K, Thomson C, Nandra RS, Ashford RU, Cool P; BOOM Audit Group; Stevenson J. Archer JE, et al. Bone Joint J. 2023 Oct 1;105-B(10):1115-1122. doi: 10.1302/0301-620X.105B10.BJJ-2023-0443.R1. Bone Joint J. 2023. PMID: 37777202
37 results